Kristyn Gumpper-Fedus, PhD, for refining a draft of the Figure into its final form
The second figure is the more conservative one, and its closer to what tends to happen in a real-world group than only among people who complete a full course
Liraglutide (Saxenda) another GLP-1 receptor agonist, recommended by NICE (TA664) for use in specialist weight management services under defined eligibility criteria, including BMI thresholds and the presence of weight-related comorbidities
Interpretation was difficult because people with EPP may continue avoiding light even when receiving an active treatment
Weight loss medications like tirzepatide can potentially affect libido and sexual function through multiple indirect pathways, though there is no official direct link established between tirzepatide and increased libido in clinical trials or FDA labeling
Daniel Knecht, MD, MBA Vice President & Chief Clinical Innovation Officer CVS Caremark LinkedIn: 1- 2- 3- Share this post: